Pancreatic Cancer Research

ResearcherHebrew University of JerusalemActive in the last 2 years

Ayala Hubert

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5110562385. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
46
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 12

  1. Neoadjuvant SBRT and intraoperative electron radiotherapy in pancreatic cancer resection. Co-author DOI 10.1007/s00432-025-06397-2↗
  2. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  3. Methionine Aminopeptidase 2 as a Potential Target in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-857731/v1↗
  4. Rapid Clearing for High Resolution 3D Imaging of Ex Vivo Pancreatic Cancer Spheroids. Co-author DOI 10.3390/ijms21207703↗
  5. Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma. Last author DOI 10.1159/000496018↗
  6. Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A cas… Last author DOI 10.3892/mco.2018.1588↗
  7. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Co-author DOI 10.18632/oncotarget.4183↗
  8. TL-118-anti-angiogenic treatment in pancreatic cancer: a case report. Last author DOI 10.1007/s12032-013-0585-9↗
  9. Mutant KRAS is a druggable target for pancreatic cancer. Co-author DOI 10.1073/pnas.1314307110↗
  10. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable panc… Co-author DOI 10.1038/cgt.2012.10↗
  11. H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer. Co-author DOI 10.5402/2012/351750↗
  12. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Last author DOI 10.4161/cbt.12.3.16292↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gideon A. Zamir · 3 shared papers, 2020–2025 · strength 0.47
  2. Ofra Benny · 2 shared papers, 2020–2021 · strength 0.25
  3. Eliana Steinberg · 2 shared papers, 2020–2021 · strength 0.25
  4. Abed Khalaileh · 2 shared papers, 2013–2025 · strength 0.24
  5. Gianella Cornejo · 1 shared paper, 2025 · strength 0.22
  6. Philip A. Blumenfeld · 1 shared paper, 2025 · strength 0.22
  7. Ana Babić · 1 shared paper, 2024 · strength 0.13
  8. Chen Yuan · 1 shared paper, 2024 · strength 0.13
  9. Andrea J. Bullock · 1 shared paper, 2024 · strength 0.13
  10. Ehsan Irajizad · 1 shared paper, 2024 · strength 0.13
  11. Thomas E. Clancy · 1 shared paper, 2024 · strength 0.13
  12. Jacob Edward Till · 1 shared paper, 2024 · strength 0.13
  13. Roni Ben‐Ami · 1 shared paper, 2024 · strength 0.13
  14. Douglas Adam Rubinson · 1 shared paper, 2024 · strength 0.13
  15. Kimmie Ng · 1 shared paper, 2024 · strength 0.13
  16. Qiao-Li Wang · 1 shared paper, 2024 · strength 0.13
  17. Michael D. Kluger · 1 shared paper, 2024 · strength 0.13
  18. Ben Z. Stanger · 1 shared paper, 2024 · strength 0.13
  19. Andrew J. Aguirre · 1 shared paper, 2024 · strength 0.13
  20. Johannes Francois Fahrmann · 1 shared paper, 2024 · strength 0.13
  21. Brian Matthew Wolpin · 1 shared paper, 2024 · strength 0.13
  22. Erica L. Carpenter · 1 shared paper, 2024 · strength 0.13
  23. Samir Hanash · 1 shared paper, 2024 · strength 0.13
  24. Nabeel M. Bardeesy · 1 shared paper, 2024 · strength 0.13
  25. Anirban Maitra · 1 shared paper, 2024 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.